You might also like
Omnicell, Inc. (OMCL) is a global leader in medication management solutions, offering a range of products and services designed to improve the efficiency and safety of medication dispensing and administration. The company operates both domestically and internationally, providing connected devices, software, and advanced services to healthcare providers. Omnicell's offerings include automated dispensing systems, software solutions, and consumable products, as well as technical and advanced services to optimize medication management processes.
- Connected Devices, Software Licenses, and Other - Provides automated dispensing systems, including the XT Series, Central Pharmacy Dispensing Service, and IV Compounding Service, to streamline medication management in healthcare facilities.
- Advanced Services - Offers subscription-based solutions such as EnlivenHealth, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software-driven services to enhance operational efficiency and compliance.
- Technical Services - Delivers recurring technical support and maintenance services to ensure the reliability and performance of Omnicell's products.
- Consumables - Supplies recurring consumable products used in conjunction with Omnicell's devices and systems to support ongoing medication management needs.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Randall A. Lipps ExecutiveBoard | President, Chief Executive Officer, and Chairman of the Board of Directors | Randall A. Lipps has held the role of CEO and President at Omnicell since October 2002 and has served as Chairman of the Board since founding the company in September 1992. His leadership has been pivotal in driving healthcare technology innovations. | View Report → | |
Nchacha E. Etta Executive | Executive Vice President and Chief Financial Officer | Nchacha E. Etta has served as Omnicell's Executive Vice President and Chief Financial Officer since June 2023 and previously held senior roles in financial leadership at companies such as Johnson & Johnson Vision and Essilor of America, Inc. He is recognized for driving operational efficiencies and integrating acquisitions throughout his extensive career. | ||
Nnamdi Njoku Executive | Executive Vice President and Chief Operating Officer | Nnamdi Njoku is the Executive Vice President and Chief Operating Officer of Omnicell, Inc. since October 7, 2024. Previously, he served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies at Zimmer Biomet Holdings from March 2023 to September 2024 and held various executive roles at Medtronic plc. | ||
Bruce E. Scott Board | Director | Chair of University of Wisconsin, School of Pharmacy Board of Visitors | Bruce E. Scott has been a Director at Omnicell since May 2019 and actively contributes through his committee roles such as Chair of the Compensation and M&A Committees. He brings extensive healthcare and pharmacy management experience from previous leadership positions across multiple organizations. | |
Edward P. Bousa Board | Director | Audit Committee at Azenta, Inc.; ESG Committee at Azenta, Inc. | Edward P. Bousa has served as a Director at OMCL since July 2021 , leveraging his extensive financial and investment expertise on the board. Previously, he held senior investment management roles at Wellington Management Company LLC from 2005 to June 2020. | |
Eileen J. Voynick Board | director | Board Chair of AGS Health LLC | Eileen J. Voynick is a director at Omnicell, Inc. since January 5, 2024. She also has extensive leadership experience, having served as CEO of Sparta Systems from July 2011 to April 2018 and COO of Allscripts Healthcare Solutions from 2009 to 2011. | |
Joanne B. Bauer Board | Lead Independent Director | Director at Advocate Health Inc. | Joanne B. Bauer has served as a board member and Lead Independent Director of Omnicell since January 2014, where she also chairs the Compensation Committee. She brings extensive leadership experience from her executive roles at Kimberly-Clark and maintains an active directorship at Advocate Health Inc.. | |
Kaushik “Bobby” Ghoshal Board | Independent Director | Chief Commercial Officer, SaaS at ResMed Inc. | Kaushik “Bobby” Ghoshal has served as a director of Omnicell since July 2023 and is a member of the Board’s Corporate Governance Committee. He has an extensive background in digital health and cloud computing, having held senior roles at ResMed Inc. including Chief Commercial Officer, SaaS. | |
Mark W. Parrish Board | Director | Director and Vice Chairman of Viatris, Inc.; Chairman of Safecor; President of the International Federation of Pharmaceutical Wholesalers; Senior Adviser to Frazier Healthcare Ventures | Mark W. Parrish has served as a Director of Omnicell since January 2013 and, until the 2024 Annual Meeting, acted as the Chair of the Audit Committee while also serving on the Compensation Committee. He brings extensive healthcare leadership experience from his previous roles as CEO and Executive Chairman of TridentUSA Health Services and from management roles at Cardinal Health. | |
Mary Garrett Board | Director | President of M. Power Coaching and Consulting, LLC; Director at PROCEPT BioRobotics Corp. | Mary Garrett has served as a Director at Omnicell since May 2022, leveraging her extensive expertise in technology and marketing. She actively contributes to board oversight by serving on the Corporate Governance Committee and will soon join the Compensation Committee. | |
Robin G. Seim Board | Director | Robin G. Seim has been serving as a Director at Omnicell since March 2019. Previously, he held executive roles including CFO from January 2006 to August 2015 and President of Global Automation and Medication Adherence from March 2016 until March 2019. |
- With the completion of the XT upgrade cycle and the expectation of lower XT replacement bookings in 2025, how do you plan to offset this decline and sustain product bookings growth, particularly through the adoption of new products like XT Amplify and XTExtend?
- Given that a competitor is releasing new dispensary cabinets this year, are you experiencing increased competitive pressures, especially in attracting health systems outside of your installed base, and how do you intend to expand your market share under these conditions?
- Considering potential tariff impacts and supply chain challenges, what specific strategies have you implemented to mitigate risks to your gross margins, and can you elaborate on how you will manage any cost increases while maintaining pricing flexibility?
- As Annual Recurring Revenue (ARR) currently represents about 53% of total revenue, can you provide more detail on the expected growth drivers within ARR for 2025, particularly the contributions from SaaS and Expert Services versus Technical Services and Consumables, and how sustainable is this growth?
- Regarding your capital deployment priorities over the next 12 months, can you elaborate on how you plan to balance investments to fuel long-term sustainable growth with the need to manage working capital in the face of evolving market dynamics?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Hub and Spoke Innovations | 2022 | Omnicell Limited acquired Hub and Spoke Innovations on January 10, 2022 for £2.5 million (approximately $3.4 million). The deal’s purchase price was allocated to goodwill (£1.9 million), intangible assets (£0.8 million, including customer relationships), and net assets, and the acquisition is strategically aimed at enhancing Omnicell's retail pharmacy technology portfolio in the UK to improve workflows and provide 24/7 medication access and enhanced patient care. |
Recent press releases and 8-K filings for OMCL.
- Q1 2025 performance: Total revenue reached $270M (10% YoY increase; $24M up) .
- Full‐year guidance update: Forecast total revenue of $1.105B–$1.155B and non‐GAAP EBITDA of $100M–$145M, incorporating tariff headwinds (≈$40M impact) and supply chain uncertainties .
- Q1 profitability: Achieved non‐GAAP EBITDA of $23.6M and non‐GAAP net income of $12M versus a GAAP net loss of $7M .
- Segment performance: Product and service revenues of $145M and $125M respectively, each up by $12M from Q1 2024 .
- Recurring revenue growth: SaaS and Expert Services are expected to represent 23% of total 2025 revenue .
- Operational strength: Boosted by the XT Amplify program, with $387M in cash and $350M in available revolving credit .
- CFO Transition: Omnicell announced that CFO Nchacha Etta will step down effective September 15, 2025, while continuing to fulfill his duties during the interim period as the company searches for a successor.
- Guidance Reiterated: The company reiterated its first quarter and full year 2025 guidance, confirming its focus on strategic priorities and long-term revenue growth.